• Source:ANI
Add as a preferred

Amid reports that PresVu eye drops, manufactured by Entod Pharmaceuticals', can help remove reading glasses in people who have presbyopia, the Mumbai-based pharmaceutical company has dismissed allegations that it made unethical or false presentation of facts to the media or public about its product. 

"We at ENTOD Pharmaceuticals hereby declare that we have not made any of the unethical or false presentation of facts to the media or public when it comes to PresVu eye drops. All facts disclosed to the media are strictly on the basis of the approved indication for treatment of presbyopia in adults and the Phase 3 clinical trial data generated by us,” Nikkhil K Masurkar, CEO, Entod Pharmaceuticals, said in a statement late Thursday evening, as quoted by news agency ANI.

The company also stated that the opinions and claims featured in recent news stories do not reflect the views of Entod Pharmaceuticals or its representatives. Entod Pharmaceuticals emphasized that the extensive media coverage of the therapy has led to sensationalism and does not align with their official stance.

The company’s clarification comes as a top official source from Drug Controller General of India (DCGI) told news agency ANI that claims made by the company are unethical and a false presentation of facts.

"This is unethical and false presentation of facts," the official source told ANI. 

During the launch of its product, the company claimed that PresVu eye drop is the first eye drop in India specifically designed to reduce reliance on reading glasses for individuals with presbyopia, a common age-related vision issue affecting those over 40.

"PresVu is the result of years of dedicated research and development. This DCGI approval is a major step forward in our mission to transform eye care in India. PresVu is more than just a product; it's a solution that stands to improve the lives of millions by offering them greater visual independence. We take pride in our commitment to innovation and in providing healthcare solutions that are both accessible and affordable." said Masurkar, CEO of ENTOD Pharmaceuticals.

The eyes drops will be reportedly available in pharmacies for Rs 350 starting from October this year, but only with a prescription. The eye drops received final approval from the Drug Controller General of India (DCGI) following a recommendation from the Central Drugs Standard Control Organisation's (CDSCO) Subject Expert Committee (SEC).